Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia

Psychiatry Research

Volumn 200, Issue 2-3, 2012, Pages 1014-1017

  Ferrari, Marco ^a   Bolla, Emilio ^a   Bortolaso, Paola ^a   Callegari, Camilla ^a   Poloni, Nicola ^a   Lecchini, Sergio ^a   Vender, Simone ^a   Marino, Franca ^a   Cosentino, Marco ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Cytochrome; Pharmacogenetic; Schizophrenia

Indexed keywords

CLOZAPINE; CYTOCHROME P450 1A2; MESSENGER RNA;

ADULT; ADVERSE OUTCOME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYP1A2 GENE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENOTYPING TECHNIQUE; HUMAN; LYMPHOCYTE; MALE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CYTOCHROME P-450 CYP1A2; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SCHIZOPHRENIA;

EID: 84872387438     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.07.002     Document Type: Article

References (19)

1. American Psychiatric Association (APA), 2000. Diagnostic and Statistical Manual of Mental Disorder, 4th edition, Text Revision. Washington.
2. Bièche I., Narjoz C., Asselah T., Vacher S., et al. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenetics and Genomics 2007, 17:731-742.
3. *1C associated with clozapine tolerability? A preliminary investigation. Psychiatry Research 2011, 189:483.
4. Bondolfi G., Morel F., Crettol S., Rachid F., et al. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Therapeutic Drug Monitoring 2005, 27:539-543.
5. Citrome L., Bilder R.M., Volavka J. Managing treatment-resistant schizophrenia: evidence from randomized clinical trials. Journal of Psychiatric Practice 2002, 8:205-215.
6. Croissant B., Hermann D., Olbrich R. Reduction of side effects by combining clozapine with amisulpride: case report and short review of clozapine-induced hypersalivation-a case report. Pharmacopsychiatry 2005, 38:38-39.
7. Doude van Troostwijk L.J., Koopmans R.P., Vermeulen H.D, Guchelaar H.J. CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients. European Journal of Pharmaceutical Sciences 2003, 20:451-457.
8. Eap C.B., Bender S., Jaquenoud Sirot E., Cucchia G., et al. Nonresponse to Clozapine and Ultrarapid CYP1A2 Activity. Clinical Data and Analysis of CYP1A2 Gene. Journal of Clinical Pharmacology 2004, 24:214-219.
9. Harrell F., Califf R., Pryor D., Lee K., Rosati R. Evaluating the Yield of Medical Tests. Journal of the American Medical Association 1982, 247:2543-2546.
10. Ingelman-Sundberg M., Sim S.C., Gomez A., Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacology & Therapeutics 2007, 116:496-526.
11. Khan A.Y., Preskorn S.H. Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. Journal of Psychiatric Practice 2005, 11:289-301.
12. *1D do not affect clozapine clearance in a group of schizophrenic patients. Annals of Clinical Biochemistry 2005, 42:216-219.
13. Martignoni E., Cosentino M., Ferrari M., Porta G., et al. Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism. Neurology 2005, 65:1820-1822.
14. McGee S. Simplifying likelihood ratios. Journal of General Internal Medicine 2002, 17:646-649.
15. Melkersson K.I., Scordo M.G., Gunes A., Dahl M.L. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. Journal of Clinical Psychiatry 2007, 68:697-704.
16. Nakajima M., Yokoi T., Mizutani M., Kinoshita M., et al. Genetic polymorphism in the 5c-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. The Journal of Biochemistry 1999, 125:803-808.
17. Ozdemir V., Kalow W., Okey A.B., Lam M.S., et al. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. Journal of Clinical Psychopharmacology 2001, 21:603-607.
18. Perlis R.H., Ganz D.A., Avorn J., Schneeweiss S., et al. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. Journal of Clinical Psychopharmacology 2005, 25:427-434.
19. Zhang W.V., D'Esposito F., Edwards R.J, Ramzan I., et al. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes. Drug Metabolism and Disposition 2008, 36:2547-2555.